Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to “Buy” Rating by Wall Street Zen

Wall Street Zen cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a research note issued to investors on Sunday morning.

Several other equities analysts have also issued reports on SUPN. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Stifel Nicolaus boosted their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Finally, Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $53.87 on Friday. The stock has a market cap of $3.10 billion, a PE ratio of -79.22, a price-to-earnings-growth ratio of 1.67 and a beta of 0.70. The stock has a 50-day moving average of $50.99 and a 200-day moving average of $48.82. Supernus Pharmaceuticals has a one year low of $29.16 and a one year high of $59.68.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares in the company, valued at $781,153.36. This trade represents a 56.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bethany Sensenig sold 4,475 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $51.01, for a total value of $228,269.75. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 25,185 shares of company stock worth $1,268,022. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in SUPN. Sit Investment Associates Inc. raised its holdings in Supernus Pharmaceuticals by 0.4% during the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after purchasing an additional 250 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares during the last quarter. Arizona State Retirement System lifted its holdings in Supernus Pharmaceuticals by 1.7% in the third quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock valued at $791,000 after buying an additional 277 shares during the period. Hantz Financial Services Inc. lifted its holdings in Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 281 shares during the period. Finally, Maryland State Retirement & Pension System boosted its position in Supernus Pharmaceuticals by 3.6% during the fourth quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after acquiring an additional 290 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.